Tag: commission

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Caribou (CRBU) To Contact Him Directly To Discuss Their Options

New York, July 25, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") for its client Garden Stage Limited (NASDAQ: GSIW) (“GSIW” or the “Company”), a Hong Kong-based financial services provider.

CORYDON, Ind., July 25, 2025 (GLOBE NEWSWIRE) -- First Capital, Inc. (the “Company”) (NASDAQ: FCAP), the holding company for First Harrison Bank (the “Bank”), today reported net income of $3.8 million, or $1.13 per diluted share, for the quarter ended June 30, 2025, compared to net income of $2.8 million, or $0.85 per diluted share, for the quarter ended June 30, 2024.

HAVERTOWN, Pa., July 25, 2025 (GLOBE NEWSWIRE) -- AMREP Corporation (NYSE:AXR) today reported net income of $12,716,000, or $2.37 per diluted share, for its 2025 fiscal year ended April 30, 2025 compared to net income of $6,690,000, or $1.25 per diluted share, for the same period of the prior year. Revenues were $49,694,000 for fiscal 2025 and $51,369,000 for fiscal 2024.

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the “Offering”). The aggregate gross proceeds to the Company from the Offering was approximately $4 million, before deducting underwriting discounts and commissions and other offering expenses.

Transaction in Own Shares

Revenue Growth of 17.6% to HK$78.7 Million (US$10.1 million); Strong Cash Position of HK$84.9 Million (US$10.9 million)

Revenue Growth of 17.6% to HK$78.7 Million (US$10.1 million); Strong Cash Position of HK$84.9 Million (US$10.9 million)

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025